Conmed is leaving the NASDAQ and transferring its listing to the New York Stock Exchange.
Conmed will begin trading on the NYSE Feb. 10. It will retain the same ticker symbol, CNMD. CEO Curt Hartman said the move will align Conmed with the "high-performing medical device companies traded on the NYSE."
NYSE Chief Commercial Officer John Tuttle spoke highly of Conmed, saying, "We look forward to collaborating with the company and continuously delivering the benefits of our unique market model and world-class services."